Form 4: AbbVie Director Edward J. Rapp Increases Stake Through Stock Equivalent Unit Acquisition
Insider Transaction Report
AbbVie Director Edward J. Rapp acquired 177 stock equivalent units valued at $185.62 per unit, increasing his beneficial ownership to 27,785 units, as part of director fee compensation.
Summary
- Edward J. Rapp, a Director of AbbVie Inc. (ABBV), acquired 177 stock equivalent units.
- The transaction occurred on June 30, 2025, with each unit valued at $185.62.
- These stock equivalent units represent director fees credited to a grantor trust established by Mr. Rapp.
- The units are generally paid in cash when Mr. Rapp reaches age 65 or retires from the board.
- The stock equivalent units are designed to earn the same return as if the director fees were directly invested in AbbVie common stock.
- Following this transaction, Mr. Rapp's total beneficial ownership of stock equivalent units stands at 27,785.
- The reported balance of 27,785 units includes additional stock equivalent units acquired through a dividend reinvestment feature.
Sentiment
Score: 7
Explanation: The sentiment is positive as it indicates a director increasing their stake in the company, aligning their interests with shareholders. While the amount is small, it's a positive signal of commitment and confidence, even if it's part of a compensation plan.
Positives
- The acquisition of stock equivalent units by a director indicates continued alignment of management interests with those of shareholders.
- The structure of director compensation through stock equivalent units ties director remuneration directly to the company's stock performance.
Future Outlook
The document does not provide any forward-looking statements or guidance beyond the nature of the stock equivalent units being paid in cash generally at age 65 or upon retirement.
Industry Context
This transaction is a routine insider filing for director compensation, common across publicly traded companies in all industries, including the pharmaceutical sector where AbbVie operates. It reflects standard corporate governance practices for aligning director interests with shareholder value.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Compensation Structure | Director fees are credited to a stock equivalent unit account under a grantor trust, with units earning the same return as AbbVie stock and generally paid in cash at age 65 or upon retirement. | 06/30/2025 | This structure aligns director compensation with shareholder returns, promoting long-term value creation and demonstrating a commitment to performance-based remuneration. |
Related Party Transactions
- The acquisition of stock equivalent units by Edward J. Rapp, a director, as part of his compensation, constitutes a related party transaction.
Stakeholder Impact
- Shareholders: The transaction demonstrates continued alignment of a director's financial interests with shareholder value, as the units' value is tied to AbbVie's stock performance.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of transaction for the acquisition of stock equivalent units and the date the derivative security became exercisable and expired. |
| 07/02/2025 | Date the Form 4 filing was signed and submitted to the SEC. |
Recommendation
holdKeywords
AbbVie, ABBV, Edward J. Rapp, Director, SEC Form 4, Insider Transaction, Stock Equivalent Units, Beneficial Ownership, Corporate Governance, Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.